The University of Notre Dame Australia

ResearchOnline@ND
IES Papers and Journal Articles

Institute for Ethics and Society

2020

Advanced cancer patient preferences for receiving molecular profiling
results
Megan Best
The University of Notre Dame Australia, megan.best@nd.edu.au

Phyllis Butow
Chris Jacobs
Ilona Juraskova
Jacqueline Savard

See next page for additional authors

Follow this and additional works at: https://researchonline.nd.edu.au/ies_article
Part of the Bioethics and Medical Ethics Commons
This article was originally published as:
Best, M., Butow, P., Jacobs, C., Juraskova, I., Savard, J., Meiser, B., Goldstein, D., Ballinger, M., Bartley, N., Napier, C., Davies, G.,
Thomas, D., Tucker, K., Schlub, T., & Newson, A. J. (2020). Advanced cancer patient preferences for receiving molecular profiling
results. Psycho-Oncology, Early View Online First.
Original article available here:
10.1002/pon.5446

This article is posted on ResearchOnline@ND at
https://researchonline.nd.edu.au/ies_article/4. For more
information, please contact researchonline@nd.edu.au.

Authors
Megan Best, Phyllis Butow, Chris Jacobs, Ilona Juraskova, Jacqueline Savard, Bettina Meiser, David
Goldstein, Mandy Ballinger, Nicci Bartley, Christine Napier, Grace Davies, David Thomas, Kathy Tucker,
Timothy Schlub, and Ainsley J. Newson

This article is available at ResearchOnline@ND: https://researchonline.nd.edu.au/ies_article/4

Copyright ©2020 John Wiley & Sons Ltd. All rights reserved.
This is the peer reviewed version of the following article:
Best, M., Butow, P., Jacobs, C., Juraskova, I., Savard, J., Meiser, B., Goldstein, D., Ballinger,
M., Barley, N., Napier, C., Davies, G., Thomas, D., Tucker, K., Schlub, T., and Newson, A.J.
(2020). Advanced cancer patient preferences for receiving molecular profiling results.
Psycho-Oncology, Early View Online First, doi: 10.1002/pon.5446
This article has been published in final form at: https://doi.org/10.1002/pon.5446

This article may be used for non-commercial purposes in accordance with Wiley Terms and
Conditions for self-archiving.

Advanced cancer patient preferences for receiving molecular profiling results
Running title: Patient preferences for receiving molecular profiling results

Megan Best, megan.best@sydney.edu.au 1,2
Phyllis Butow, phyllis.butow@sydney.edu.au 1
Chris Jacobs, chris.jacobs@uts.edu.au 3
Ilona Juraskova ilona.juraskova@sydney.edu.au 1
Jacqueline Savard, jacqueline.savard@deakin.edu.au 4
Bettina Meiser b.meiser@unsw.edu.au 5
David Goldstein d.goldstein@unsw.edu.au 5
Mandy Ballinger, m.ballinger@garvan.org.au 6
Nicci Bartley, nicole.bartley@sydney.edu.au 1
Christine Napier, c.napier@garvan.org.au 6
Grace Davies, grace.davies@sydney.edu.au 1
David Thomas, d.thomas@garvan.org.au 6
Kathy Tucker, kathy.tucker@health.nsw.gov.au 5
Timothy Schlub tim.schlub@sydney.edu.au 1
Ainsley J Newson, ainsley.newson@sydney.edu.au 1
And members of the PiGeOn Project.
1) University of Sydney
2) University of Notre Dame Australia
3)

University of Technology, Sydney

4) Deakin University, Geelong
5)

University of NSW, Sydney

6)

Garvan Institute of Medical Research, Sydney

Correspondence to: Dr Megan Best, PoCoG, Level 6 North, Lifehouse C39Z, University of Sydney NSW
2006.

KEYWORDS
Cancer, genetic testing, molecular profiling, oncology, patient preference, personalised medicine, results,
bioethics, qualitative research, attitudes

This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as doi:
10.1002/pon.5446

This article is protected by copyright. All rights reserved.

ABSTRACT
Objective
This study aimed to discern preferences for receiving somatic molecular profiling (MP) results in cancer
patients who have given consent to undergo testing.
Methods
We conducted a mixed-methods study to explore patients’ views on which MP results they would like to
receive and why. Advanced cancer patients (n=1299) completed questionnaires after giving consent to
participate in a parent genomics study and undergoing MP. A subset of patients (n=20) participated in
qualitative interviews.
Results
Almost all (96%) participants were interested in receiving results which would direct cancer treatment (i.e.
were actionable). A smaller majority wanted to access results which were not actionable (64%) or were
variants of unknown significance (60%). Most (86%) were interested in finding out about germline
findings, though not as a priority. Themes identified in interview data were: 1) Cancer is the focus; 2)
Trust in clinicians; and 3) Respect for a right not to know.
Conclusions
The majority of advanced cancer patients undergoing MP prioritised results which would lead to treatment
options. They trusted their oncologists to help them navigate the results return process. While there was
interest in knowing about other results, this was a lesser priority. Nevertheless, given high levels of
interest in receiving all results, ethical aspects of not providing uninformative results requires further
research, including a consideration of patient rationales for desiring this information and what health
professionals can and should do to support patients in the absence of meaningful information being
available.
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BACKGROUND
Precision medicine is advancing in oncology, with increasing use of genomic testing to identify cancer risk
and guide treatment.(1) Testing in the advanced cancer setting includes somatic molecular profiling (MP),
involving panel testing of solid tumours to identify cancer-specific gene mutations, which can be linked to
cognate therapies.(2)
MP can identify variants that: a) inform treatment (clinically actionable), b) do not inform treatment (nonactionable), c) are of uncertain therapeutic significance (VUS), or d) have a germline origin (and therefore
have relevance to the patient’s family). If a clinically actionable result is returned, the relevant treatment
may or may not be accessible to the patient.
Research evidence is mixed regarding patient preferences for receiving MP results. While the promise of
novel treatment attracts cancer patients to genomic testing, (3, 4) germline findings can be perceived as
burdensome by patients due to incapacity caused by progressive disease, (5) and there is some
confusion about non-actionable findings. (4) Concerns have also been expressed about low genomic
literacy in patients leading to misunderstanding of results, generating anxiety and uncertainty about the
future. (3) It is important to understand the perspectives of patients regarding MP results, in order to
support them adequately during testing. This mixed methods study aimed to examine the preferences
for receiving results of advanced cancer patients who were actually undergoing MP (under a research
protocol) in order to access novel therapies.(6)
METHODS
Participants were recruited to the Molecular Screening and Therapeutics (MoST) cancer genomic study,
which is recruiting adult patients with pathologically confirmed advanced or metastatic solid cancers (of
any histological type) who have exhausted therapeutic options.(6) Participants undergo MP and, if an
actionable variant is found, are enrolled in a related therapeutic trial if available. Participants can elect to
receive actionable, non-actionable and/or germline results at the time of consent, and to allow germline
results to be returned to family members in the event of the participant’s death.
The Psychosocial Issues in Genomics in Oncology (PiGeOn) Project is a longitudinal, mixed methods
psychosocial sub-study for MoST which aims to examine the psychosocial and behavioural impacts and
ethical issues for MP.(7) Patients give written consent to this study and the parent study at the same time.
Both studies were approved by the St Vincent’s Hospital Human Research Ethics Committee (Reference
HREC/16/SVH/23).
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Data collection
From the PiGeOn study, this paper focuses on participants’ preferences regarding MP results. All
participants were asked to complete a questionnaire just after consent was given (prior to MP), which
included a hypothetical question regarding whether they would like to receive actionable, non-actionable,
variants of unknown significance (VUS) or germline results. A subset of participants were invited to
participate in a semi-structured telephone interview within 1-2 weeks of giving consent. Purposive
sampling was used to ensure a heterogeneous sample. Interviews were conducted by one researcher
(NB) and continued until data saturation was reached. Questions asked included which results
participants would like to receive and why, and the expected impact of results. See Interview Schedule
(Supplementary Table 1). Questions were developed iteratively to develop themes identified during the
study analysis. Demographic details were collected by the parent study.
Analysis
Demographic data were tabulated and summary statistics used to describe questionnaire results (Tables
1 and 2, respectively). Analysis of variables potentially associated with the desire to receive each type of
result was performed using logistic regression using IBM SPSS Statistics Version 25. Variables
investigated included age, sex, education, urban versus rural/remote place of residence, English as first
language, medical-science occupation, whether participants had biological children, whether any first
degree relatives were diagnosed with cancer, time since diagnosis and cancer incidence (rare, less
common, common). See Supplementary Tables 2-5.
Interviews were recorded and transcribed. Using thematic analysis (8), data was coded and formed into
focused codes which were applied to further transcripts, and developed into themes. Data collection and
analysis occurred concurrently as themes were refined and applied to the data. Any differences between
researchers were resolved through discussion and negotiated consensus. Rigor was derived from
successive discussions and review of the coding process by researchers until theoretical coding was
complete. The varied academic backgrounds of the researchers ensured reflexivity, and comparison of
qualitative and quantitative results provided triangulation of data.

RESULTS
Participants in the MoST study (n=1299) were evenly distributed in gender (52% female), with mean age
of 56 years, and mixed cancer diagnoses with an average Eastern Cooperative Oncology Group (ECOG)
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rating between 0 and 1. The qualitative cohort (n=20) had a mean age of 57 years, 45% female, with
mixed cancer diagnoses and an average ECOG rating between 0 and 1.
Quantitative results
Of the 1299 MoST questionnaire participants, 1252 (96%) indicated a preference to receive actionable
results, 836 (64%) elected to receive non-actionable results, 601 (60%) would like to receive VUS, and
1119 (86%) wanted to receive germline results which could inform family risk (see Table 2).
Logistic regression indicated that patients who were more interested in being informed about actionable
gene variants had an English-speaking background (p = .038), biological children (p = .034) or a first
degree relative with cancer (p = .031). See Supplementary Table 2.
Patients’ higher educational background and remote/rural location were significant predictors of wanting
to be informed about non-actionable gene variants (p = .002) and (p < .001) respectively. Living in a
remote area was a significant predictor of wanting to be informed about VUS (p = .003). See
Supplementary Tables 3 and 4.
Younger patient age, parental status and having a relative with cancer, were all significant predictors of
wanting to receive information about germline results that could inform family members’ risk (p = .020), (p
= .005) and (p = .034) respectively. See Supplementary Table 5.
Qualitative results
Three themes were identified in the transcripts: 1) Cancer is the focus, 2) Trust in clinicians and 3)
Respect for a right not to know. Perspectives were significantly influenced by the patient’s clinical
situation.
1.

Cancer is the focus

a)

Cancer information first

All participants interviewed prioritised receiving information about variants linked to possible cancer
treatments. They were concerned that non-actionable information might confuse them. Interest was also
expressed in receiving results in a staggered way, with cancer information prioritised.
I think most important for somebody with cancer is to get that treatment information to them as
pure and understandable as possible
information at the first port [of call]

Conflating it with non-relevant – non-treatment

is not a good idea. Male 42 years
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However, this did not mean that participants were not interested in other results. When giving consent,
participants were told there was a chance of receiving a germline result. Interviewees realised that,
although not necessarily important for themselves (given their advanced cancer), such information would
likely be of interest to their family. As such, most did want germline information, but not as a priority.
Personally, for me, I would like to know. Already my brother has got bladder cancer and he had
another
family

skin cancer

there was a high possibility at one stage that we might be

a cancer

I’ve got a huge family, but everybody is very involved in knowing as much information

as possible

So for me personally, more information the better. My two girls

would like to know

too if there’s a family link. Female, 60 years.

Testing was not seen to be a waste of time, even if a new therapy was not found, as results were generally
considered to be beneficial for research and cancer patients in general (which could include other family
members in the future).
We sort of thought if it doesn’t help me it might help someone else. Female, 58 years
b)

VUS

Participants were asked whether (hypothetically) VUS should be returned if revealed in MP. Participants
generally understood that a VUS might be identified, given the early stage of research in this area:
My understanding is that, yes, if you find something within my DNA testing that you don't quite
understand, I realise that that is why because

the advances are happening so quickly it's hard

to keep up. Female 75 years
Despite this, many participants were optimistic that VUS results would prove useful at some point. Thus,
the explanation of potential uncertainty did not always impact their desire to hear the result.
I guess I would be a bit

disappointed, but think well, nothing ventured nothing gained. And

even...the fact that you’ve actually tested the tumor

some lightbulb might switch on somewhere

in a few years and be like, I had another one like that and it might come to some cure down the
track. Female 58 years

This article is protected by copyright. All rights reserved.

Despite not having been mentioned during the consent process (and not being required under Australian
research guidelines), several patients assumed that VUS findings would continue to be monitored into the
future.
Perhaps, if I survive long enough, then they might understand it and so, some benefit will come
from it. It can’t get any worse [and they should continue to check] as long as the cancer remains
within the community. Male, 51 years.
Participants were willing to pay for this ongoing investigation of their results.
However, not all participants felt the need to hear about non-actionable results, generally because they
did not perceive they would be useful.
I think that is really taking it a step too far. There’s no point in it

you can have too much

information. Male, 42 years.
2.

Trust in clinicians

As all participants had advanced cancer, they had relationships with a community oncologist as well as
the research team, and had confidence that the clinicians were ‘keeping an eye’ on them and ensuring
they received all relevant information.
Several participants said they would rather receive information and support from their own familiar
oncologist (rather than the study oncologist). Participants trusted their own doctors to tell them only what
was important, thus avoiding unhelpful results.
For me, yeah [I can have too much information]. You know, I have great faith in the team that
looks after me and so, I don’t need to know

all the ins and outs. Male 55 years

However, in view of the low chance of an actionable result, other clinical support was seen as an
important requirement at the point where results were communicated. For one participant:
Because the potential outcome [accessing a new treatment] is slim, and because people, by the
time they get to you, might be getting more and more desperate about some kind of solution, I
think access to social work, and that kind of more emotional support, would be a good thing for
people. Male 64 years
3.

Respect for a right not to know
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Receiving personal results was considered vital by many participants, because most had joined the study
to explore potential access to a ‘last-hope’ therapy. When asked whether participants should be able to
undergo MP but decline to receive any personal results (a question that drew on a purported ‘right not to
know’ one’s germline genetic information), the initial response was that this attitude was
incomprehensible.
I think it kind of defeats the purpose. Male 41 years
However, most participants accepted that others could hold different views, and have different needs and
responses, and respected their decision to refuse results. Clinicians were expected to ensure that the
best outcome was achieved for such patients.
Not knowing the person, it might send them all off on a different tangent mentally, and emotionally.
That’s the difficulty... I’d have to rely on the team talking to somebody that knows the person
you’d have to rely on the team talking to the family doctor about that. Female, 67 years.
Participation in the study even when results were declined was also seen as worthwhile in that it still
contributed to research and would build knowledge.
If people chose that, that’d be fine

having more participants than less is definitely a better

outcome [for research purposes]. Male 41 years
When asked whether a person should be told their results, despite refusal, if a result was found to be
potentially lifesaving, the response generally changed. More respondents adopted a clinical paradigm
(although this was a translational research project) and felt doctors had an obligation to inform such a
patient on the grounds of a perceived duty of care to the individual, or to the community.
I think it’s part of the duty of care, to try and give them the best option they could even if they
didn’t want to receive the information. Male 41 years
That’s the whole public health thing, isn’t it?.. You might not want it but I have information that will
save the public health system money, will save your life, will improve our quality of life. Male 42
years
Concern that the family could miss out on receiving results if a participant refused was also expressed:
I wonder

can you give it [the result] if the family says, “can we have it”? Female 67 years
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DISCUSSION
We conducted a mixed-methods study to explore advanced cancer patients’ views on which genomic
results they would like to receive after undergoing MP, and their broader views on this. We found that
most participants were interested in receiving results which would provide further treatments options for
their cancer. Other results, such as germline findings, were also of interest if they were perceived to have
utility, particularly for participants with children and those with a family history of cancer, but not as a
priority. A subset of participants noted that more information is always better, with hopes of future
breakthroughs, while some feared the psychological impact of burdensome information. Perspectives
were significantly influenced by the need for hope in these patients with advanced disease, who had
exhausted available treatment options.
Our paper on motivation for participation in the PiGeOn study (9) reflected the overwhelming need this
cohort had to find new treatments. MP was felt to be an important aspect of cancer management that
should be widely available in the clinical context. Other previous research has similarly found that hope
for new therapy makes MP attractive to patients, alongside concern about negative results.(4) These
findings suggest the need for information and decision tools to support physicians in communicating
realistic prospects of benefit from MP, to minimise possible patient distress.
Interest in obtaining results expressed by those with children or a first degree relative with cancer
highlights the heightened motivation for avoiding cancer that personal experience is known to
generate.(10) This study and others have, however, found that advanced cancer patients may perceive
conveying risk information to relatives as burdensome.(4) Incomplete family communication of germline
genetic information in this setting is well documented,(11) despite the so-called ‘duty to warn’ genetic
relatives.(12) Here, relevant aspects of this debate are whether it applies in a research context (13) and
to findings that are essentially ‘incidental’ to the main purpose of the test.(14) There is also recognition
that specific issues can arise concerning the sharing of information with relatives once a patient has
died.(13-15)
Some participants showed interest in receiving VUS, often assuming future utility. This preference gives
rise to the question of whether a perceived right to know generates an actual right to know – especially in
situations where resources are constrained. Arguments for granting research participants wider access to
their genomic data have been made,(16) but this would need to involve a consent process that promotes
genuine reflection on the rationale for wanting this information. Processes must also take account of
differences between people’s abilities to process and cope with this information.
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This cohort expected that any VUS identified would continue to be reviewed over time. Participants were
willing to pay for this information. A recent policy statement from the American College of Medical
Genetics and Genomics(17) suggested physicians do their best to recontact patients with updated
information. As a research study, this program has no obligation, under Australian regulations, to continue
to interrogate data after the project ceases(18). However, the translational nature of this work – with
personalised therapy as an intended output - also exemplifies the collapsing distinction between research
and practice. Thus, the question of whether researchers should continue to interrogate participant data
needs more investigation. Additionally, future consent protocols should include a discussion with
participants as to whether or not results will be updated over time, based on the individual treating
oncologist’s intentions and relevant guidelines.
Our participants expressed great confidence in their oncologists’ filtering of complex results so that only
relevant information was passed on. Given their dependence on healthcare professionals to interpret
genomic test results, oncologists’ genomic literacy is of concern. (4) This suggests that care should be
taken in deciding which findings to generate and report. Efforts to educate oncologists regarding
understanding and communicating genomic test results of all kinds are ongoing.(19)
Study Limitations
This study contained a qualitative element which is not intended to be generalizable. Other cohorts may
respond differently.
Clinical Implications
This study examined advanced cancer patients’ views on which genomic results they would like to
receive after undergoing MP. Clinicians should clearly articulate which results will be generated in order
to manage patient expectations. Consideration should be given to prioritising actionable findings, and
supporting patients who do not receive them.
Conclusion
This mixed methods study reports insights into the preferences of advanced cancer patients regarding
receiving MP results. While perceived utility was an important discriminator in what was seen as valuable
for this cohort, there were a variety of responses. In view of these, it is important to ensure engagement
with patients about test validity and utility, their expectations and ensuring their choices reflect wellconsidered preferences. This can be aided by having quality consent processes, which encompass
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provision of relevant information in a manner sensitive to participant distress and desire for additional
treatment options, and access to professional support. As the perceived utility of genomic tests can
reduce after receiving results,(20) and in view of known challenges in implementing consent
processes,(21) we suggest that patient preferences are relevant to, but not determinative of, a decision to
return uninformative results in this context, where the focus is on cancer treatment. The nature and value
of the information should guide result return. Additionally, the ethical aspects of returning uninformative
results requires further research, including consideration of patient rationales for desiring information and
what health professionals can and should do to support patients in the absence of meaningful information
being available.
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TABLES
Table 1: Demographics
Characteristics

Total participants (n=1299)

Interviews (n=20)

Mean (SD)

56.02 (14.23)

57.05 (11.44)

Median (IQR)

58 (21)

58 (15.5)

Range

18-90

41-77

Mean (SD)

3.11 (4.08)

2.1 (2.4)

Range

0-40.40

0.1-7.8

n (%)

n (%)

670 (52)

9 (45)

Age (years):

Time since Diagnosis (years)

Gender:
Female
Highest level of education
completed:
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Primary school

16 (1)

0 (0)

Year 7 or 8

35 (3)

0 (0)

Year 9 or 10

212 (16)

2 (10)

Year 11 or 12

219 (17)

1 (5)

Vocational Training

242 (19)

7 (35)

University did not graduate

17 (15)

0 (0)

University graduated

546 (42)

8 (40)

Missing

12 (0.9)

2 (10)

1170 (90)

13 (65)

291 (22)

1 (5)

Medical-Science Occupation

90 (7)

2 (10)

Has biological children

974 (75)

19 (95)

Has a first degree relative

639 (49)

6 (30)

Rare

891 (69)

13 (65)

Less Common

174 (13)

5 (25)

Common

234 (18)

2 (10)

Bone and soft tissue

244 (19)

2 (10)

Brain

139 (11)

1 (5)

Colorectal

122 (9)

0

Pancreas

113 (9)

2 (10)

Breast

67 (5)

1 (5)

Uterus

67 (5)

2 (10)

Ovary

53 (4)

1 (5)

Unknown primary

50 (4)

2 (10)

Lung

47 (4)

2 (10)

Accessibility and Remoteness
Index of Australia (ARIA):
Urban (versus rural/remote)
Culturally and Linguistically
Diverse (CALD) background

diagnosed with cancer
Cancer Incidence

Cancer Diagnosis (ICD-10)
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Prostate

36 (3)

0

Other

361 (28)

7 (35)

0

655 (50)

8 (40)

1

576 (44)

11 (55)

2

54 (4)

1 (5)

3

4 (0.3)

0 (0)

Missing

10 (0.8)

0 (0)

Mean (SD)

0.54 (0.59)

0.65 (0.59)

ECOG score

Table 2: Survey results- What sort of gene variants you would like to be informed about?
Preference

n (%)

All results

505 (50)

(N = 1007)
Gene variants that can guide treatment for my
advanced cancer
Yes

1252 (96)

No

3 (0.2)

Maybe

22 (2)

Don’t know

17 (1)

Missing

5 (0.4)

Gene variants that can NOT guide a treatment for
my advanced cancer
Yes

836 (64)

No

144 (11)

Maybe

173 (13)

Don’t know

124 (10)

Missing

22 (2)

Gene variants that no-one knows anything about

(N = 1007)

This article is protected by copyright. All rights reserved.

Yes

601 (60)

No

110 (11)

Maybe

127 (13)

Don’t know

145 (14)

Missing

24 (2)

Gene variants that provide information about my
family members’ risk of developing cancer
Yes

1119 (86)

No

43 (3)

Maybe

63 (6)

Don’t know

78 (6)

Missing

17 (1)
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